Better Stock Today: Celgene vs. American Express
Tyler Riggs and David Williamson, The Motley Fool - Motley Fool - Sat Jun 14, 1:18PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Celgene takes on American Express for...
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ...
Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA
Business Wire - Sat Jun 14, 11:30AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that a retrospective analysis of MM-003, the Company's phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination, were presented at the 19th European Hematology Association annual congress. Pomalidomide is marketed as POMALYST(R) in the United States and IMNOVID(R) in the European Union.
Results from Phase III Study (AML-001) of VIDAZA(R) (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA
Business Wire - Sat Jun 14, 7:58AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from AML-001, its phase III study of VIDAZA(R) (azacitidine for injection) compared to conventional care regimens (CCR) in elderly subjects with newly-diagnosed acute myeloid leukemia (AML - >30% blasts) were presented in a late-breaking abstract oral session at the 19th European Hematology Association annual congress. The study was presented by Pr. Herve Dombret of the Hopital Saint-Louis in Paris, France.
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia
Business Wire - Sat Jun 14, 2:00AM CDT
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced interim data from two studies of candidates from the companies' joint development program in beta-thalassemia. The data presented at the 19th European Hematology Association (EHA) annual congress show activity for two programs, sotatercept and ACE-536, in patients with both transfusion dependent and non-transfusion dependent beta-thalassemia. There is currently no drug approved to treat beta-thalassemia. Both sotatercept and ACE-536 have been granted orphan drug designation for beta-thalassemia by the United States Food and Drug Administration (FDA).
Down 9%: Is OncoMed a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jun 13, 6:05PM CDT
OncoMed shareholders had a rough day, with potential issues with mild-to-moderate bone-related adverse events causing a halt in a phase 1 trial for two of the company's drugs. The big question, of course, is whether this makes for an attractive...
Final Glance: Biotechnology companies
AP - Fri Jun 13, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST(R)) Trial Presented at EHA Annual Congress
Business Wire - Fri Jun 13, 4:44PM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that an analysis of health-related quality of life measures (HRQOL) from FIRST(R) (Frontline Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide), its phase III study (MM-020/IFM 07-01) of REVLIMID(R) (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) ineligible for stem cell transplant was presented during the 19th European Hematology Association annual congress.
Midday Glance: Biotechnology companies
AP - Fri Jun 13, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Jun 13, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Encouraging Long-Term Data on Celgene's Otezla - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 10:30AM CDT
Encouraging data on Otezla was presented by Celgene (CELG) at the EULAR.
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver
PR Newswire - Wed Jun 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JCP, BF.B, SLB, CELG, and DTV.
Oral OTEZLA(R) (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis
Business Wire - Wed Jun 11, 6:30AM CDT
--OTEZLA demonstrated a consistent safety profile with no clinically meaningful changes in laboratory measurements across three PALACE phase III studies of 1,493 patients over 52 weeks
Oral OTEZLA(R) (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naive Patients with Active Psoriatic Arthritis
Business Wire - Wed Jun 11, 6:30AM CDT
--PALACE 4 is the first and only large randomized, placebo-controlled study to examine the efficacy and safety of a single agent in patients naive to previous DMARD therapy
Agios Initiates Trial on AG-348 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 3:35PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced the initiation of a multiple ascending dose (MAD) phase I trial on pipeline candidate AG-348.